 |
Registration: 7:15 AM - 7:30 AM Registration for this program is now closed. |
|
Program Overview:
Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy decreases cardiovascular morbidity and mortality in patients with heart failure (HF). Evidence-based HF guidelines support the titration of RAASi to achieve target doses to optimize treatment benefits. However, RAASi also increases the risk of hyperkalemia. Hyperkalemia, an electrolyte disorder characterized by elevated levels of serum potassium, is a barrier to optimization of RAASi therapy in patients with HF. Unfortunately, down-titration or discontinuation of RAASi treatment is a common strategy to manage hyperkalemia in routine clinical practice; these actions place HF patients at increased risk of major adverse clinical events. Novel potassium binders effectively and safely lower serum potassium, potentially enabling HF patients to remain on optimal RAASi therapy. In this program, experts will 1) identify HF medications that increase the risk for hyperkalemia, 2) emphasize the importance of patients taking RAASi therapy and at target doses, 3) discuss the clinical evidence for using novel potassium binders for the treatment of hyperkalemia, and their potential impact in facilitating optimization of RAASi therapy to reduce patient cardiovascular risk, and 4) explain the rationale for using novel potassium binders in long-term management |
|
|
Educational Objectives: Accreditation & Credit Designation: Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1.5 Credits Educational Grant:Voxmedia and the Heart Failure Society of America (HFSA) gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals. Disclosure Statement: Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices. | |
